Can Personalized Neoantigens Raise the T Cell Bar?

Neeha Zaidi

doi:10.1016/j.cell.2020.09.053

Can Personalized Neoantigens Raise the T Cell Bar?

Neeha Zaidi

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.

Original language	English (US)
Pages (from-to)	301-302
Number of pages	2
Journal	Cell
Volume	183
Issue number	2
DOIs	https://doi.org/10.1016/j.cell.2020.09.053
State	Published - Oct 15 2020

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2020.09.053

Cite this

@article{6893ca3fe49743a0a67428afcd8e4b4a,

title = "Can Personalized Neoantigens Raise the T Cell Bar?",

abstract = "Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.",

author = "Neeha Zaidi",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

day = "15",

doi = "10.1016/j.cell.2020.09.053",

language = "English (US)",

volume = "183",

pages = "301--302",

journal = "Cell",

issn = "0092-8674",